Skip to main content
Company profile
Phio Pharmaceuticals Corp. logo

Phio Pharmaceuticals Corp.

Pipeline3 assets

  • PH-762PH-762 / PD-1 / INTASYL (sdRNA) / Oncology
    Cutaneous Squamous Cell CarcinomaMelanomaMerkel Cell Carcinoma
  • PH-894PH-894 / BRD4 / INTASYL (sdRNA) / Oncology / Infectious Disease
    Advanced MelanomaMerkel Cell CarcinomaHepatocellular Carcinoma
  • PH-804PH-804 / TIGIT / INTASYL (sdRNA) / Oncology
    Cancer

Latest news16 items

All news

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Brings extensive experience in patient care, dermatologic research and commercialization King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer....

Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026

Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attend King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer....

Phio Pharmaceuticals Corp. • Endpoint Arena